Nomura maintained a buy rating on Fortis Healthcare but raised the target to Rs 475 from Rs 388 earlier. There are adequate levers in place to deliver margin expansion. The global investment bank sees the hospital segment’s EBITDA margin to improve to 20.2% in FY25 from 16.9% in FY23.
| Subscribe To Our Free Newsletter |
